IAMBIC THERAPEUTICS, INC.

CHANGE IN CONTROL AND SEVERANCE PLAN

AND SUMMARY PLAN DESCRIPTION

1. Introduction. The purpose of this Iambic Therapeutics, Inc. Change in Control and Severance Plan (the “Plan”) is to provide assurances of specified benefits to certain employees of the Company whose employment could be being involuntarily terminated under the circumstances described in the Plan. This Plan is adopted by the Board effective as of the Effective Date, and upon the Effective Date, this Plan will supersede any severance benefits which may be available to a Participant under an individual agreement between any member of the Company Group and the Participant which is in effect as of the Effective Date. This Plan is an “employee welfare benefit plan,” as defined in Section 3(1) of ERISA. This document is both the written instrument under which the Plan is maintained and the required summary plan description for the Plan.

…

Exhibit10.8

Iambic Therapeutics, Inc.

Confirmatory Executive Offer Letter

September 18, 2026

Michael Secora

Dear Dr. Secora:

This letter agreement (the “Agreement”) is entered into between Iambic Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the effective date of the first registration statement that is filed by the Company and declared effective pursuant to Section 12(b) of the Exchange Act with respect to the Company’s common stock (the “Effective Date”). The purpose of this Agreement is to confirm the terms and conditions of your continued employment with the Company as of the Effective Date.

1.

…

EMPLOYMENT AGREEMENT

This Employment Agreement (“Agreement”) is made on and effective as of the date signed by the last party to sign on the signature page below.

Between

(1)

IAMBIC THERAPEUTICS UK LTD, incorporated and registered in England and Wales with company number 12789012 whose registered office is at [***] (the “Company”, “we” or “us”); and

(2)

Frederick Manby of [***] (the “Employee” or “you”)

Agreed terms

1.

Interpretation

1.1.

The definitions and rules of interpretation in this clause 1 apply in this Agreement.

“Associated Employer” has the meaning given to it in the Employment Rights Act 1996.

“Board” means the board of directors of Iambic Therapeutics, Inc. (including any committee of the board duly appointed by it).

“Business Day” means a day, other than a Saturday, Sunday or public holiday in England, when banks in London are open for business.

“Employee Handbook” means the Company’s employee handbook (if any) as amended from time to time.

“Employment” means your employment by us on the terms of this Agreement.

…

[***] Certain information in this document has been omitted from this exhibit pursuant to Item 601(b) of Regulation S-K because it is both not material and is the type that the Registrant treats as private or confidential.

Collaboration and Option Agreement

Between

Iambic Therapeutics, Inc.

and

H. Lundbeck A/S

1

---

COLLABORATION AND OPTION AGREEMENT

This COLLABORATION AND OPTION AGREEMENT (the “Agreement”) is entered into as of September 23, 2024 (the “Effective Date”) between Iambic Therapeutics, Inc., a Delaware corporation, having its principal place of business at 5627 Oberlin Drive, Suite 120, San Diego, California 92121 (“Iambic”) and H. Lundbeck A/S, a Danish corporation, having its principal place of business at Ottiliavej 9, 2500 Valby, Denmark (“Lundbeck”). Lundbeck and Iambic each may be referred to herein individually as a “Party” or collectively as the “Parties.” All attached appendices, exhibits and schedules are a part of this Agreement.

RECITALS

…

[***] Certain information in this document has been omitted from this exhibit pursuant to Item 601(b) of Regulation S-K because it is both not material and is the type that the Registrant treats as private or confidential.

RESEARCH COLLABORATION AND LICENSE AGREEMENT

DATED AS OF FEBRUARY 3, 2026

BY AND BETWEEN

IAMBIC THERAPEUTICS, INC.

AND

TAKEDA PHARMACEUTICALS, U.S.A., INC.

---

TABLE OF CONTENTS

ARTICLE 1.	DEFINITIONS	1
ARTICLE 2.	LICENSES; DATA RIGHTS; EXCLUSIVITY	25
2.1	License Grants to Takeda	25
2.2	License Grant to Iambic	25

…

Iambic Therapeutics, Inc.

Confirmatory Executive Offer Letter

September 18, 2026

Thomas Miller

Dear Dr. Miller:

This letter agreement (the “Agreement”) is entered into between Iambic Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the effective date of the first registration statement that is filed by the Company and declared effective pursuant to Section 12(b) of the Exchange Act with respect to the Company’s common stock (the “Effective Date”). The purpose of this Agreement is to confirm the terms and conditions of your continued employment with the Company as of the Effective Date.

1.

…

CONSULTING AGREEMENT

This Consulting Agreement (“Agreement”) is entered into as of May 11, 2026, (the “Effective Date”), between AnaptysBio, Inc., a Delaware corporation having its principal place of business in San Diego, California (“Company” or “Anaptys”), and Chris Murphy, an individual whose address is Rancho Santa Fe, California 92067 (“Consultant”, and collectively with the Company, the “Parties”).

WHEREAS, Consultant has agreed to provide consulting services to the Company following on the terms and conditions set forth in this Agreement;

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual agreements contained herein, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows with respect to the services to be rendered by the Consultant:

1.

…

SUBLEASE AGREEMENT

This Sublease Agreement (“Sublease”) is dated as of June 15, 2026 (the “Effective Date”), by and between ANAPTYSBIO, INC., a Delaware corporation (“Sublandlord”), and FIRST TRACKS BIOTHERAPEUTICS, INC., a Delaware corporation, (“Subtenant”).

RECITALS

A.Sublandlord currently leases certain premises from WATERIDGE PROPERTY OWNER, LP, a Delaware limited partnership (the “Master Landlord”), pursuant to the terms and conditions of that certain Lease dated May 4, 2020, as amended by that certain First Amendment to Lease Agreement, dated April 5, 2021 (as so amended, the “Master Lease”). Pursuant to the Master Lease, Sublandlord currently leases from Master Landlord approximately 45,057 rentable square feet of space (the “Premises”) located in that certain building located in 10770 Wateridge Circle, San Diego, CA 92121 (the “Building”), as more specifically described in the Lease. Sublandlord represents that a true, correct and complete copy of the Master Lease is attached hereto as Exhibit A. All terms capitalized but undefined herein shall have the meanings ascribed

…

Amendment No. 1 to Employment Agreement

September 18, 2026

​

​

This Amendment No. 1 to Employment Agreement (this “Amendment”) is entered into effective as of September 18, 2026 (the “Amendment Effective Date”), by and between Orion Group Holdings, Inc., a Delaware corporation (the “Company”), and Travis J. Boone (“Key Employee”). The Company and Key Employee are referred to together as the “Parties” and individually as a “Party.”

RECITALS

WHEREAS, the Company and Key Employee are parties to that certain Employment Agreement dated effective September 27, 2023 (the “Employment Agreement”);

WHEREAS, the Initial Term of the Employment Agreement currently is scheduled to expire on September 19, 2026;

WHEREAS, the Board of Directors of the Company (the “Board”) or a duly authorized committee of the Board has approved an extension of the Initial Term and the addition of an automatic annual-renewal mechanism; and

WHEREAS, the Parties desire to amend the Employment Agreement solely as expressly provided in this Amendment.

…

Amendment No. 1 to Employment Agreement

September 18, 2026

​

​

This Amendment to Employment Agreement (this “Amendment”) is entered into effective as of September 18, 2026 (the “Amendment Effective Date”), by and between Orion Group Holdings, Inc., a Delaware corporation (the “Company”), and E. Chipman Earle (“Key Employee”). The Company and Key Employee are referred to together as the “Parties” and individually as a “Party.”

RECITALS

WHEREAS, the Company and Key Employee are parties to that certain Employment Agreement dated effective March 20, 2024 (the “Employment Agreement”);

WHEREAS, the Initial Term of the Employment Agreement currently is scheduled to expire on September 19, 2026;

WHEREAS, the Board of Directors of the Company (the “Board”) or a duly authorized committee of the Board has approved an extension of the Initial Term and the addition of an automatic annual-renewal mechanism; and

WHEREAS, the Parties desire to amend the Employment Agreement solely as expressly provided in this Amendment.

…

TRANSITION AND RELEASE AGREEMENT

This Transition and Release Agreement (the “Agreement”) is made and entered into by and among John Mitchell (“Employee”), PACS Group, Inc. (“PubCo”) and Providence Administrative Consulting Services, Inc. (together with PubCo, the “Company”). This Agreement shall be effective on the date on which Employee executes this Agreement (the “Effective Date”). The purpose of this Agreement is to provide separation pay to ease Employee’s transition from the Company in connection with Employee’s retirement, to provide for the transition of Executive’s role with the Company from that of Chief Legal Officer to that of a non-employee consultant to the Company, effective as of the Separation Date (as defined below), and to settle and resolve any and all disputes and controversies of any nature existing between Employee and the Company, including, but not limited to, any claims arising out of Employee’s employment with, and separation from, the Company.

1.Separation of Employment.

…

THIS CONVERTIBLE PROMISSORY NOTE (“NOTE”) AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), APPLICABLE STATE LAW, OR APPLICABLE LAWS OF ANY FOREIGN JURISDICTION, AND MAY NOT BE SOLD, OFFERED FOR SALE, DISTRIBUTED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (A) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE OR FOREIGN SECURITIES LAWS COVERING ANY SUCH TRANSACTION OR (B) SUCH TRANSACTION IS EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE STATE OR FOREIGN SECURITIES LAWS COVERING SUCH TRANSACTION.

CONVERTIBLE PROMISSORY NOTE

Principal Amount: $500,000.00	September 15,2026

…